The mid-esophagus including phase II and phase III, patients are usually no distant metastases, there may be regional lymph node metastasis. It seems that esophageal medium-term treatment is still surgery, postoperative pathological conditions, you can choose adjuvant radiotherapy, chemotherapy and biological therapy.
Some info about esophageal Cancer
Esophageal cancer known as esophageal cancer is a malignant tumor in the esophageal epithelial tissue, accounting for 2% of all malignant tumors. Annually about 22 million people died of esophageal cancer in the world, more patients are older than 40 years, more men than women, but in recent years, patients present a younger trend. The incidence of esophageal cancer is related to and nitrosamines chronic irritation, inflammation and trauma, genetic factors as well as drinking water, food and vegetables in the trace element contents.
Some scholars believe that the medium-term treatment of esophageal cancer may consider preoperative chemotherapy, which may improve the survival rate, in which chemotherapy was effective, significantly prolonged survival. But most hospitals often choose the first surgery, radiotherapy and chemotherapy treatment option that is operative concurrent radiation and drug therapy, the use of chemicals to enhance the effect of radiation therapy. For mid-term esophageal cancefor patients with unresectable, a single use of concurrent radiotherapy and chemotherapy without surgery also have a fairly good control effect.
The preoperative and postoperative chemotherapy, preoperative and postoperative radiotherapy, radiotherapy alone, chemotherapy alone or chemotherapy and radiotherapy is the the esophagus medium-term use of the more common treatment options. Another clinical treatment is called electrochemical intervention with the particle stent technology used for the treatment of esophageal mid. Particularly suitable for the older with more comorbidities in weak physical condition and those cannot accept patients with surgery or other treatment owing to physical defects.
Esophageal medium-term treatment cannot blindly pursue surgery or radiotherapy and chemotherapy. The standard treatment of science is to consider the patient’s condition and physical condition together.